
BLUE
Healthcare · Biotechnology · $48.7M market cap
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 7, 2025 | Before the open | -4.63 | -2.66 | +42.5% |
| Mar 24, 2025 | Before the open | -6.29 | -2.84 | +54.9% |
| Nov 5, 2024 | Before the open | -0.36 | -0.31 | +13.9% |
| Aug 14, 2024 | Time not confirmed | -6.80 | -8.40 | -23.5% |
| May 9, 2024 | Time not confirmed | -8.20 | -7.20 | +12.2% |
| Mar 26, 2024 | Time not confirmed | -11.20 | -15.60 | -39.3% |
| Nov 7, 2023 | Before the open | -0.67 | -0.66 | +1.5% |
| Aug 8, 2023 | Before the open | -0.72 | -0.67 | +6.9% |
| May 9, 2023 | Before the open | -0.37 | 0.21 | +156.8% |
| Mar 29, 2023 | Before the open | -0.44 | -0.81 | -84.1% |
| Nov 7, 2022 | Before the open | -1.12 | -0.94 | +16.1% |
| Aug 4, 2022 | After the close | -1.24 | -1.27 | -2.4% |
| May 9, 2022 | After the close | -1.39 |
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a…
| -1.66 |
| -19.4% |
| Mar 4, 2022 | After the close | -1.88 | -2.14 | -13.8% |
| Nov 5, 2021 | Before the open | -2.59 | -3.16 | -22.0% |
| Aug 9, 2021 | Before the open | -3.25 | -3.43 | -5.5% |
| May 5, 2021 | After the close | -3.01 | -3.07 | -2.0% |
| Feb 23, 2021 | After the close | -2.92 | -3.01 | -3.1% |
| Nov 4, 2020 | After the close | -3.05 | -2.94 | +3.6% |
| Aug 5, 2020 | After the close | -2.60 | -0.36 | +86.2% |
| May 11, 2020 | Before the open | -4.01 | -3.64 | +9.2% |
| Feb 18, 2020 | After the close | -3.79 | -4.04 | -6.6% |
| Oct 31, 2019 | After the close | -3.52 | -3.73 | -6.0% |
| Aug 1, 2019 | After the close | -3.06 | -3.55 | -16.0% |
| May 2, 2019 | After the close | -2.80 | -2.99 | -6.8% |
| Feb 21, 2019 | After the close | -2.86 | -2.72 | +4.9% |
| Nov 1, 2018 | After the close | -2.87 | -2.73 | +4.9% |
| Aug 2, 2018 | Before the open | -2.35 | -2.91 | -23.8% |
| May 2, 2018 | After the close | -2.07 | -2.31 | -11.6% |
| Feb 21, 2018 | After the close | -1.70 | -2.52 | -48.2% |